Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase.
Zambrano JN, Williams CJ, Williams CB, Hedgepeth L, Burger P, Dilday T, Eblen ST, Armeson K, Hill EG, Yeh ES. Zambrano JN, et al. Among authors: armeson k. Oncotarget. 2018 Nov 13;9(89):35962-35973. doi: 10.18632/oncotarget.26311. eCollection 2018 Nov 13. Oncotarget. 2018. PMID: 30542510 Free PMC article.
HUNK phosphorylates EGFR to regulate breast cancer metastasis.
Williams CB, Phelps-Polirer K, Dingle IP, Williams CJ, Rhett MJ, Eblen ST, Armeson K, Hill EG, Yeh ES. Williams CB, et al. Among authors: armeson k. Oncogene. 2020 Jan;39(5):1112-1124. doi: 10.1038/s41388-019-1046-5. Epub 2019 Oct 9. Oncogene. 2020. PMID: 31597954 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33574278
Correction: HUNK phosphorylates EGFR to regulate breast cancer metastasis.
Williams CB, Phelps-Polirer K, Dingle IP, Williams CJ, Rhett MJ, Eblen ST, Armeson K, Hill EG, Yeh ES. Williams CB, et al. Among authors: armeson k. Oncogene. 2021 May;40(20):3635-3636. doi: 10.1038/s41388-021-01797-3. Oncogene. 2021. PMID: 33958726 Free PMC article. No abstract available.
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.
Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, Singh S, Uribarri J, Garrett-Mayer E, Armeson KE, Hilton EJ, Clair MJ, Taylor MH, Abbott AM, Findlay VJ, Peterson LL, Magwood G, Turner DP. Walter KR, et al. Among authors: armeson ke. Breast Cancer Res Treat. 2019 Feb;173(3):559-571. doi: 10.1007/s10549-018-4992-7. Epub 2018 Oct 27. Breast Cancer Res Treat. 2019. PMID: 30368741 Free PMC article.
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. Somaiah N, et al. Among authors: armeson ke. Cancer. 2021 Mar 15;127(6):894-904. doi: 10.1002/cncr.33216. Epub 2020 Nov 24. Cancer. 2021. PMID: 33231866 Free article. Clinical Trial.
64 results